The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: 0.00 (0.00%)
Spread: 2.00 (0.017%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 12,050.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 3-Berlin earmarks 9 bln euros to buy COVID-19 shots for Europeans

Tue, 09th Feb 2021 16:53

(Adds German health ministry, background)

By Michael Nienaber

BERLIN, Feb 9 (Reuters) - Germany is planning to spend
nearly 9 billion euros ($10.9 billion) this year to help procure
up to 635.1 million COVID-19 vaccination shots for its
population and other EU member states, a finance ministry
document seen by Reuters showed on Tuesday.

Delays to the EU's vaccine roll-out and concerns about new
coronavirus variants are making it harder for Berlin and other
European governments to ease pandemic restrictions. The hiccups
have caused some tensions between Brussels and Berlin.

Finance Minister Olaf Scholz's deputy Bettina Hagedorn
proposed to lawmakers in a letter that they should approve a
request by Health Minister Jens Spahn for an additional 6.22
billion euros to buy more doses, according to the document.

This comes on top of 2.66 billion euros already earmarked in
the 2021 budget.

The additional spending plans come after Scholz told the BBC
over the weekend that he was angry that more COVID-19 vaccines
were not ordered last year at a European level while EU chief
executive Ursula von der Leyen renewed her defence of the
European Commission's record on rolling them out.

A coalition source told Reuters the Bundestag lower house of
parliament's budget committee was expected to approve the
additional spending on Wednesday.

"For the federal government, obtaining COVID-19 vaccines is
of fundamental importance to get the pandemic under control,"
Hagedorn told lawmakers in the letter.

"In addition, a broad portfolio (of vaccines) is required so
that Germany will have effective vaccines with enough vaccine
doses for the various population groups, also in the case that
not all vaccines are approved," she added.

The Health Ministry will use the total funds of 8.89 billion
euros to buy up to 635.1 million vaccine doses as part of the
European Union's joint procurement plan and Berlin's national
efforts to secure additional shots, the document said.

All EU member states have agreed to procure vaccines under
the bloc's joint plan in an attempt to avoid a race among member
states which could have left poorer countries with fewer doses.

A German health ministry spokesman said Berlin would use 456
million euros of the overall 8.89 billion euros to procure
vaccine doses in bilateral agreements with companies. The lion's
share would be used as part of the EU procurement plan.

Under the EU agreement, member states are not allowed to
conduct parallel talks and sign side deals with vaccine makers
who negotiate with the EU.
($1 = 0.8258 euros)

(Reporting by Michael Nienaber;
Additional reporting by Francesco Guarascio in Brussels and
Andreas Rinke in Berlin;
Editing by Caroline Copley and Alison Williams)

More News
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
9 Jan 2024 10:50

Novartis in advanced talks to buy Cytokinetics- source

Jan 9 (Reuters) - Swiss drugmaker Novartis is in the lead to acquire Cytokinetics in a deal that could value the drug developer at well over $10 billion, a source familiar with the matter said on Monday.

Read more
8 Jan 2024 14:08

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
6 Jan 2024 17:44

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
5 Jan 2024 12:00

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
3 Jan 2024 17:48

London close: Stocks fall amid rising geopolitical concerns

(Sharecast News) - London stocks closed lower on Wednesday - the 40th anniversary of the FTSE 100's launch - as sentiment remained cautious due to increasing tensions in the Middle East.

Read more
3 Jan 2024 16:52

LONDON MARKET CLOSE: Stocks down ahead of US Fed minutes

(Alliance News) - Stock prices in London closed lower on Wednesday, as investors nervously look ahead to the latest US Federal Reserve meeting minutes.

Read more
3 Jan 2024 11:07

Jefferies upgrades GSK to 'buy', cuts AstraZeneca to 'hold'

(Sharecast News) - Jefferies has upgraded its rating on GlaxoSmithKline to 'buy' and cut AstraZeneca to 'hold' as part of its review of the European pharma sector.

Read more
3 Jan 2024 10:16

IN BRIEF: Nuformix narrows annual loss as develops drug assets

Nuformix PLC - London-based developer of treatments for fibrosis and oncology via drug repurposing - Pretax loss narrows to GBP927,972 in 18 months that ended September 30 from GBP1.3 million in the 12 months that ended March 31, 2022, following its change of financial year-end. Has no meaningful revenue in either period, so reduced loss is due to lower administrative expenses.

Read more
3 Jan 2024 10:12

AIM WINNERS & LOSERS: C4X gets Astra payment; Getech wins eight deals

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
3 Jan 2024 09:23

LONDON BROKER RATINGS: GSK raised to 'buy'; AstraZeneca cut to 'hold'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
3 Jan 2024 08:58

LONDON MARKET OPEN: Stocks mixed pre-Fed minutes, amid Asia losses

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of US Federal Reserve meeting minutes and manufacturing PMI data for the US in the evening and afternoon respectively.

Read more
3 Jan 2024 08:04

C4X receives USD11 million from AstraZeneca following NRF2 trials

(Alliance News) - C4X Discovery Holdings PLC on Wednesday said it has received payment from AstraZeneca PLC following trials of the C4X respiratory disease therapy treatment.

Read more
3 Jan 2024 07:54

LONDON BRIEFING: Stocks to open flat pre-Fed minutes, jobs data

(Alliance News) - The FTSE 100 is expected to open flat on Wednesday, as London's flagship index celebrates its 40th anniversary, after mostly downbeat trading in Asia and a tech sell-off in New York.

Read more
2 Jan 2024 17:05

British equities slip on higher yields, financials drag

FTSE 100 down 0.2%, FTSE 250 off 0.9%

*

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.